# The ELG Analysis of Glucose a Correlational to Blood Glucose Assay

Study · id `cardio:ct-nct05055804` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05055804](<https://clinicaltrials.gov/study/NCT05055804>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05055804

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05055804. Allocation not applicable; no masking; primary purpose supportive care. Start 2021-08-11 (actual); primary completion 2025-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose supportive care
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05055804, source copy `cardio:ctgov-nct05055804-2025-01-16`, retrieved 2026-10-26)
- Started: 2021-08-11 (actual) (ClinicalTrials.gov record NCT05055804, source copy `cardio:ctgov-nct05055804-2025-01-16`, retrieved 2026-10-26)
- Primary completion: 2025-10 (anticipated) (ClinicalTrials.gov record NCT05055804, source copy `cardio:ctgov-nct05055804-2025-01-16`, retrieved 2026-10-26)
- Completion: 2025-11 (anticipated) (ClinicalTrials.gov record NCT05055804, source copy `cardio:ctgov-nct05055804-2025-01-16`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05055804, source copy `cardio:ctgov-nct05055804-2025-01-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05055804-2025-01-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: The ELG Analysis of Glucose a Correlational to Blood Glucose Assay
- Condition: Diabetes Mellitus, Type 1
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): ELG
- Lead sponsor: XP Technology, LLC
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: e21e3626f0e95fcdae63b876f20112255206f587f5fb0f7c6858dc7325ebcf10
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
